Using multiple doses of Remicade as salvage therapy for acute severe ulcerative colitis produced better colectomy-free outcomes for patients at 3 months, according to results of a meta-analysis.
However, Peter P. De Cruz, MBBS, PhD, FRACP, of the department of gastroenterology at Austin Health in Australia, and colleagues wrote that the drug’s true benefit might be masked because it is used more often in patients with worse disease severity.
“Despite being used for more than 15 years, the optimal [Remicade; infliximab, Janssen] dose strategy in [acute severe ulcerative colitis

Source link